Assay News and Research

RSS

Limewater combination therapy can reduce root canal endotoxins

Treating root canals with a combination of chlorhexidine gel and calcium hydroxide results in significant reduction of endotoxins and neutralization of cytotoxic effects compared with the gel plus polymyxin B or saline, report Brazilian researchers.

17 Jul 2012

Life Technologies acquires Navigenics

Life Technologies Corporation today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies' first step in executing against a strategy to build out its molecular diagnostics business through internal development, partnerships and select acquisitions.

17 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Abbott to showcase new informatics and lab solutions at AACC annual meeting

Abbott will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today's laboratories will be the focal point of the Abbott exhibit.

16 Jul 2012

Sandia researchers develop SpinDx medical diagnostic tool

Researchers at Sandia National Laboratories have developed a lab-on-a-disk platform that they believe will be faster, less expensive and more versatile than similar medical diagnostic tools.

14 Jul 2012

New assay can identify rare cancerous cells within mixed populations

Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.

12 Jul 2012

PCR assay ‘superior’ to culture for neonatal sepsis, meningitis

In neonates with probable sepsis or meningitis, a realtime polymerase chain reaction assay specific for a virulence gene in Streptococcus agalactiae is superior to standard bacterial culture identification, results of a pathology study show.

11 Jul 2012

Courtagen launches nucSEEKPDx assay

Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced the expansion of their genetic test menu. The new genetic test, nucSEEKPDx, will sequence approximately 1,100 nuclear genes constituting the mitochondrial exome, which encodes the vast majority of proteins found in the mitochondrion. This test is by far the most comprehensive test on the market for the management of mitochondrial disorders.

11 Jul 2012

Genetic test helps avoid needless thyroid surgery

US researchers report that a gene-based test may help to identify patients who have cytologically indeterminate thyroid nodules that are benign.

10 Jul 2012

TNF-α levels linked to lithium response in BD patients

Patients with bipolar disorder who have a poor response to lithium treatment have significantly higher serum levels of tumor necrosis factor-α than those with a good response, researchers report.

10 Jul 2012

Abbott announces CE Marking for ARCHITECT HbA1c assay

More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

10 Jul 2012

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

10 Jul 2012

SurModics IVD to introduce BioFX TMB Extended Range HRP Microwell Substrate

SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.

9 Jul 2012

BioView, ScreenCell enter collaboration agreement for imaging of CTC

BioView Ltd. and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit.

9 Jul 2012

Critical Diagnostics showcases Presage ST2 Assay at AAHFN annual meeting

Critical Diagnostics, makers of the Presage ST2 Assay, participated in the annual meeting for the American Association of Heart Failure Nurses in Chicago, considered the premier meeting in heart failure nursing.

3 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

Oxytocin levels linked to medication dose, symptoms in schizophrenia

Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.

29 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Health Canada approves AutoGenomics’ INFINITI PGx testing system

AutoGenomics, a leader in providing automated, molecular microarray testing solutions, announced today that they have received their first Health Canada Medical Device Class III approvals for their automated INFINITI Pharmacogenomic (PGx) testing system.

28 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012